Education
About Us
Working with TipRanks
Follow Us
Harmony Biosciences Holdings (HRMY)
NASDAQ:HRMY
RESEARCH TOOLSreports
HRMY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$26.47 - $41.61
Previous CloseN/A
Volume87.33K
Average Volume (3M)738.65K
Market Cap
$1.66B
Enterprise Value$1.77B
Total Cash (Recent Filing)$332.98M
Total Debt (Recent Filing)$193.06M
Price to Earnings (P/E)11.6
Beta1.58
Next Earnings
May 06, 2025EPS Estimate
0.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.51
Shares Outstanding57,386,690
10 Day Avg. Volume794,606
30 Day Avg. Volume738,651
Financial Highlights & Ratios
PEG Ratio0.64
Price to Book (P/B)N/A
Price to Sales (P/S)2.83
Price to Cash Flow (P/CF)6.70
P/FCF Ratio6.40
Enterprise Value/Market Cap1.06
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.17
Enterprise Value/Ebitda7.88
Forecast
1Y Price Target
$54.00Price Target Upside85.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Harmony Biosciences Holdings News
PremiumCompany Announcements
Harmony Biosciences Appoints Ron Philip to Board
PremiumCompany Announcements
Harmony Biosciences Appoints New Chief Commercial Officer
PremiumCompany Announcements
Harmony Biosciences Earnings Call Highlights Growth and Challenges
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsTop-line data from RECONNECT are expected to support the first FDA approval for any treatment targeting the behavioral symptoms of FXS.
Financial PerformanceHRMY is seen as a profitable, commercial-stage company with a deep pipeline, a strong balance sheet, and excellent visibility on the catalyst calendar through 2027/2028.
Product DevelopmentThe announcement of a patent settlement with a first generic challenger sets a 2030 generic Wakix launch, which is seen as a positive development for HRMY.
Bears Say
Clinical Development RiskRisks include clinical development risk tied to pitolisant GR, pitolisant HD, ZYN002, and EPX100.
Revenue ExpectationsLast month's setback for pitolisant for idiopathic hypersomnia/IH still stings, leading to reset revenue expectations for HRMY.
---
Ownership Overview
26.59% Insiders
21.38% Mutual Funds
25.47% Other Institutional Investors
1.26% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HRMY FAQ
What was Harmony Biosciences Holdings’s price range in the past 12 months?
Harmony Biosciences Holdings lowest stock price was $26.47 and its highest was $41.61 in the past 12 months.
What is Harmony Biosciences Holdings’s market cap?
Harmony Biosciences Holdings’s market cap is $1.66B.
When is Harmony Biosciences Holdings’s upcoming earnings report date?
Harmony Biosciences Holdings’s upcoming earnings report date is May 06, 2025 which is in 22 days.
How were Harmony Biosciences Holdings’s earnings last quarter?
Harmony Biosciences Holdings released its earnings results on Feb 25, 2025. The company reported $0.85 earnings per share for the quarter, beating the consensus estimate of $0.734 by $0.116.
Is Harmony Biosciences Holdings overvalued?
According to Wall Street analysts Harmony Biosciences Holdings’s price is currently Undervalued.
Does Harmony Biosciences Holdings pay dividends?
Harmony Biosciences Holdings does not currently pay dividends.
What is Harmony Biosciences Holdings’s EPS estimate?
Harmony Biosciences Holdings’s EPS estimate is 0.63.
How many shares outstanding does Harmony Biosciences Holdings have?
Harmony Biosciences Holdings has 57,386,690 shares outstanding.
What happened to Harmony Biosciences Holdings’s price movement after its last earnings report?
Harmony Biosciences Holdings reported an EPS of $0.85 in its last earnings report, beating expectations of $0.734. Following the earnings report the stock price went up 8.163%.
Which hedge fund is a major shareholder of Harmony Biosciences Holdings?
Currently, no hedge funds are holding shares in HRMY
---
Harmony Biosciences Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$54.00 (85.12% Upside)
$54.00 (85.12% Upside)
Blogger Sentiment
Bullish
HRMY Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 61.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $278.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 0.9%
Last 30 Days ▲ 0.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.68%
12-Months-Change
Fundamentals
Return on Equity
25.84%
Trailing 12-Months
Asset Growth
23.14%
Trailing 12-Months
Company Description
Harmony Biosciences Holdings
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
---
HRMY Company Deck
---
HRMY Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong performance in terms of revenue growth and patient base expansion for Harmony Biosciences. Significant advancements in their pipeline, including multiple ongoing and upcoming Phase 3 trials, highlight a solid strategy for future growth. However, the rejection of the Pitolisant sNDA and challenges in clinical trials for idiopathic hypersomnia present notable setbacks. Despite these challenges, the company's financial stability and strategic moves, such as the generic settlement, contribute to an overall positive outlook.Read More>---
HRMY Stock 12 Month Forecast
Average Price Target
$54.00
▲(85.12% Upside)
Technical Analysis
Denali Therapeutics
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Kymera Therapeutics
―
Recursion Pharmaceuticals
―
Best Analysts Covering HRMY
1 Year
1 Year Success Rate
5/13 ratings generated profit
1 Year Average Return
-3.83%
reiterated a buy rating 4 months ago
Copying David Amsellem's trades and holding each position for 1 Year would result in 38.46% of your transactions generating a profit, with an average return of -3.83% per trade.
---